347 related articles for article (PubMed ID: 33268483)
1. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
[TBL] [Abstract][Full Text] [Related]
3. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
4. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
5. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
[TBL] [Abstract][Full Text] [Related]
6. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
7. Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display.
Zielonka S; Krah S; Arras P; Lipinski B; Zimmermann J; Boje AS; Klausz K; Peipp M; Pekar L
Methods Mol Biol; 2023; 2681():231-248. PubMed ID: 37405651
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
[TBL] [Abstract][Full Text] [Related]
9. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
10. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
Front Immunol; 2021; 12():801368. PubMed ID: 35087526
[TBL] [Abstract][Full Text] [Related]
11. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
Cao G; Wang J; Zheng X; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Dec; 290(50):29964-73. PubMed ID: 26472927
[TBL] [Abstract][Full Text] [Related]
12. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
[TBL] [Abstract][Full Text] [Related]
13. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.
Kaifu T; Escalière B; Gastinel LN; Vivier E; Baratin M
Cell Mol Life Sci; 2011 Nov; 68(21):3531-9. PubMed ID: 21877119
[TBL] [Abstract][Full Text] [Related]
14. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
[TBL] [Abstract][Full Text] [Related]
15. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
[TBL] [Abstract][Full Text] [Related]
16. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
[TBL] [Abstract][Full Text] [Related]
19. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
Li Y; Wang Q; Mariuzza RA
J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
